Prevention of osteoporosis as a consequence of hormone treatment in postmenopausal women treated for breast cancer
Finish Year: 2012
Chief Investigator: Associate Professor Sharon Kilbreath
Institution: University of Sydney
Priority-driven Collaborative Cancer Research Scheme (PdCCRS)
Aromatase inhibitors, a first-line treatment for the postmenopausal women treated for breast cancer, have improved the prognosis of breast cancer by at least 20%. However, one side-effect is a rapid decrease in bone mineral density. Without an effective intervention to address osteoporosis, health costs will increase significantly.
This project is co-funded by NBCF and Cancer Australia.